Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US

Current Medical Research and Opinion, 2016 02; 32(2): 385-394

This study aimed to compare time on treatment (TOT) among patients treated with everolimus and chemotherapy, two commonly used treatments for hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC).

View abstract

Authors

Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.